<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56301">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373202</url>
  </required_header>
  <id_info>
    <org_study_id>LTS13618</org_study_id>
    <secondary_id>U1111-1160-6525</secondary_id>
    <nct_id>NCT02373202</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To document the long-term safety of sarilumab added to non-methotrexate (non-MTX)
      disease-modifying antirheumatic drugs (DMARDs) or as monotherapy.

      Secondary Objective:

      To document the long term efficacy of sarilumab added to non-MTX DMARDs or as monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total study duration is up to 62 weeks: Up to 4-week screening period, 52-week treatment
      period, and 6-week post-treatment follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>58 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in vital signs</measure>
    <time_frame>58 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in electrocardiogram (ECG)</measure>
    <time_frame>58 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in laboratory values</measure>
    <time_frame>58 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving ACR20/50/70 responses</measure>
    <time_frame>58 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Disease Activity Score 28 (DAS28)-CRP</measure>
    <time_frame>58 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Health Assessment Questionnaire-Disability Index scores</measure>
    <time_frame>58 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SC) injection of Dose 1 once in 2 weeks (q2w)
non-MTX DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin) (stable dose) are continued as background therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of Dose 2 q2w
non-MTX DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin) (stable dose) are continued as background therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of Dose 3 q2w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of Dose 4 q2w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sarilumab SAR153191 (REGN88)</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous</description>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 1</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 2</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 3</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-MTX DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin)</intervention_name>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 1</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulfasalazine</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 1</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leflunomide</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 1</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bucillamine</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 1</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Pharmaceutical form: capsule Route of administration: oral</description>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 1</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mizoribin</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 1</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191 [REGN88]) Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Diagnosis of rheumatoid arthritis (RA), according to the American College of
        Rheumatology/The European League Against Rheumatism (ACR/EULAR) 2010 Rheumatoid Arthritis
        Classification Criteria with ≥3 months disease duration.

        Moderately to severely active RA defined as:

          -  At least 4 of 68 tender joints and 4 of 66 swollen joints at screening visit.

          -  High sensitivity C-Reactive Protein (hs-CRP) ≥4mg/L or Erythrocyte sedimentation rate
             (ESR) ≥28 mm/hr at screening visit. For the combination stratum:

        Patients who had continuous treatment with non-biologic DMARDs other than MTX for at least
        12 weeks prior to the randomization.

        OR Patients who per investigator judgment were any of inappropriate, intolerant or
        inadequate to MTX treatment.

        Exclusion criteria:

        Patients &lt;20 years of age. Prior treatment with tumor necrosis factor (TNF) antagonists or
        any other RA-directed biologic agents without the appropriate off-drug period prior to
        screening.

        Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor (IL-6R)
        antagonist therapies, including but not limited to tocilizumab or sarilumab.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392010</name>
      <address>
        <city>Asahi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Asahikawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392070</name>
      <address>
        <city>Beppu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392036</name>
      <address>
        <city>Chiba-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392083</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392004</name>
      <address>
        <city>Fukui-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392039</name>
      <address>
        <city>Fukuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392030</name>
      <address>
        <city>Ichinomiya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Iizuka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392019</name>
      <address>
        <city>Kagoshima-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392066</name>
      <address>
        <city>Kamakura-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392050</name>
      <address>
        <city>Kato-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392037</name>
      <address>
        <city>Kawachi-Nagano-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392099</name>
      <address>
        <city>Kawasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392013</name>
      <address>
        <city>Kitakyushu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392097</name>
      <address>
        <city>Kochi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392065</name>
      <address>
        <city>Kushiro-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392026</name>
      <address>
        <city>Matsuyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392034</name>
      <address>
        <city>Miyagi-Gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392076</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392080</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392046</name>
      <address>
        <city>Narashino-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392059</name>
      <address>
        <city>Oita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392062</name>
      <address>
        <city>Okayama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392027</name>
      <address>
        <city>Osaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392049</name>
      <address>
        <city>Sagamihara-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392014</name>
      <address>
        <city>Sapporo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392041</name>
      <address>
        <city>Sapporo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392073</name>
      <address>
        <city>Sapporo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392006</name>
      <address>
        <city>Sasebo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392021</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392022</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392033</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392071</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392029</name>
      <address>
        <city>Shizuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392023</name>
      <address>
        <city>Takaoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392003</name>
      <address>
        <city>Tomakomai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392074</name>
      <address>
        <city>Urasoe-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392079</name>
      <address>
        <city>Urayasu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392048</name>
      <address>
        <city>Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 8, 2016</lastchanged_date>
  <firstreceived_date>February 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
    <mesh_term>Bucillamine</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
